Amgen is a leading biotechnology company that focuses on the development, manufacturing, and commercialization of innovative therapeutic solutions to treat serious illnesses. The company leverages its advanced science and research capabilities to create biologic therapies that target various medical conditions, including cancer, kidney disease, and rheumatoid arthritis. Through a commitment to scientific excellence, Amgen aims to enhance patient care by providing effective treatments that improve health outcomes and quality of life. Additionally, the company engages in extensive research collaborations and partnerships, further advancing its mission to deliver groundbreaking therapies to patients around the world. Read More
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie (NYSE:ABBV).
Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the inflammatory disease market.
Sandoz is seeking an injunction to prevent Amgen from using patent rights to block biosimilar competition and allow Sandoz to launch its Erelzi “as soon as possible.”
President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on pharmaceuticals imported from foreign countries.
Dip-buying absent in early NY trading, Wall Street deep in red as trade war fears escalate despite strong jobs report. Investors on edge for hints from Fed Chair Powell.
The FDA approved Amgen's Uplizna as the first treatment for IgG4-RD. The decision is backed by the MITIGATE trial, showing reduced flares and sustained efficacy.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).
